{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:17:43Z","timestamp":1762460263814,"version":"3.41.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objects<\/jats:title>\n<jats:p>Tenofovir Alafenamide (TAF) is a novel antiviral drug approved for the treatment of hepatitis B virus (HBV) infection. Our research objective was to evaluate the safety characteristics of TAF in practical settings by analyzing data from the FDA adverse event reporting system (FAERS) database maintained by the Food and Drug Administration (FDA).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Method<\/jats:title>\n<jats:p>In our investigation, we examined the uneven distribution of adverse events associated with TAF by employing statistical metrics including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Gamma-Poisson Shrinker (GPS) to determine their significance.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Out of the 57692002 case reports in the FAERS database, 1911 reported TAF as a major suspected (PS) adverse events (AEs). A disproportionate analysis identified 43 preferred terms (PTs) related to TAF. It is worth noting that we have observed unexpected significant adverse events, such as cerebral infarction, bone pain, swallowing difficulties, drug resistance, dementia, etc., which are not mentioned in the drug instructions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>These findings unearth novel neurological, metabolic, and resistance - related risks, thereby necessitating a marked increase in clinical vigilance. The identification of signals related to cerebral infarction and dementia implies potential vascular\/metabolic interplay, highlighting the importance of lipid monitoring among long - term tenofovir alafenamide (TAF) users. In response, healthcare providers should prioritize strengthening the monitoring of neurological symptoms and lipid profiles, reevaluating bone health assessment and management protocols especially in high - risk populations, and providing support to enhance patient adherence to mitigate resistance risks. This analysis offers crucial post - marketing evidence, which is instrumental in optimizing the risk - benefit balance of TAF in the long - term management of chronic hepatitis B virus (HBV) infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0324675","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:53:18Z","timestamp":1749145998000},"page":"e0324675","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS)"],"prefix":"10.1371","volume":"20","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3881-8425","authenticated-orcid":true,"given":"Yinghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"10204","key":"pone.0324675.ref001","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"394","author":"M Zhou","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"pone.0324675.ref002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"W Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"pone.0324675.ref003"},{"issue":"11","key":"pone.0324675.ref004","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.15725","article-title":"Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients","volume":"51","author":"G-A Kim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"10159","key":"pone.0324675.ref005","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"KJ Foreman","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"pone.0324675.ref006","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0324675.ref007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"AS Ray","year":"2016","journal-title":"Antiviral Res"},{"issue":"2","key":"pone.0324675.ref008","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0324675.ref009","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"pone.0324675.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"SK Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"2","key":"pone.0324675.ref011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","article-title":"Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B","volume":"38","author":"AK Singal","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0324675.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"E De Clercq","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"pone.0324675.ref013","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Y Wang","year":"2024","journal-title":"Andrology"},{"key":"pone.0324675.ref014","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"B Zhao","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0324675.ref015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"H Yang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"pone.0324675.ref016","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"B Zhao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"pone.0324675.ref017","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine","volume":"23","author":"C Zhong","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"pone.0324675.ref018","doi-asserted-by":"crossref","first-page":"100847","DOI":"10.1016\/j.jhepr.2023.100847","article-title":"Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"5","author":"Y-S Lim","year":"2023","journal-title":"JHEP Rep"},{"issue":"4","key":"pone.0324675.ref019","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u00a0weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"K Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0324675.ref020","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"B Fernandez-Fernandez","year":"2011","journal-title":"AIDS Res Treat"},{"issue":"1","key":"pone.0324675.ref021","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"PE Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pone.0324675.ref022","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","article-title":"Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results","volume":"72","author":"D Wohl","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9987","key":"pone.0324675.ref023","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"PE Sax","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"pone.0324675.ref024","doi-asserted-by":"crossref","first-page":"350","DOI":"10.46234\/ccdcw2024.066","article-title":"Comparison of Statistical Signal Detection Methods in Adverse Events Following Immunization - China, 2011-2015","volume":"6","author":"L Xia","year":"2024","journal-title":"China CDC Wkly"},{"issue":"4","key":"pone.0324675.ref025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bcpt.13944","article-title":"BCPT 2023 policy for experimental and clinical studies","volume":"133","author":"P Tveden-Nyborg","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"pone.0324675.ref026","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review","volume":"7","author":"CJ Alberts","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"pone.0324675.ref027","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study","volume":"3","author":"BG Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"pone.0324675.ref028","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review","volume":"7","author":"CJ Alberts","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"pone.0324675.ref029","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/14787210.2018.1428561","article-title":"Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?","volume":"16","author":"M Vigan\u00f2","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"pone.0324675.ref030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.micpath.2019.01.004","article-title":"Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma","volume":"128","author":"VK Chaturvedi","year":"2019","journal-title":"Microb Pathog"},{"issue":"4","key":"pone.0324675.ref031","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","article-title":"Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis","volume":"10","author":"M M\u00fcller","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0324675.ref032","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/apt.17765","article-title":"Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B","volume":"59","author":"P-N Cheng","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"pone.0324675.ref033","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","article-title":"Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety","volume":"119","author":"HLY Chan","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"pone.0324675.ref034","doi-asserted-by":"crossref","DOI":"10.1161\/ATV.0000000000000164","article-title":"Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association","volume":"43","author":"LB Goldstein","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:53:25Z","timestamp":1749146005000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324675"}},"subtitle":[],"editor":[{"given":"Douglas S.","family":"Krakower","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324675","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}